These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37044035)

  • 1. EZH2 inhibition dampens autoantibody production in lupus by restoring B cell immune tolerance.
    Yang Y; Li M; Zhu Y; Liu K; Liu M; Liu Y; Zhu G; Luo H; Zuo X; Zhang H; Guo M
    Int Immunopharmacol; 2023 Jun; 119():110155. PubMed ID: 37044035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice.
    Wu L; Jiang X; Qi C; Zhang C; Qu B; Shen N
    Front Immunol; 2021; 12():653989. PubMed ID: 33868295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ezh2 Knockout in B Cells Impairs Plasmablast Differentiation and Ameliorates Lupus-like Disease in MRL/lpr Mice.
    Zheng X; Dozmorov MG; Strohlein CE; Bastacky S; Sawalha AH
    Arthritis Rheumatol; 2023 Aug; 75(8):1395-1406. PubMed ID: 36897808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus.
    Urbonaviciute V; Starke C; Pirschel W; Pohle S; Frey S; Daniel C; Amann K; Schett G; Herrmann M; Voll RE
    Arthritis Rheum; 2013 Jun; 65(6):1612-23. PubMed ID: 23450347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR4
    Ma K; Li J; Wang X; Lin X; Du W; Yang X; Mou F; Fang Y; Zhao Y; Hong X; Chan KW; Zhang X; Liu D; Sun L; Lu L
    Ann Rheum Dis; 2018 Oct; 77(10):1498-1506. PubMed ID: 29925508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methionine Commits Cells to Differentiate Into Plasmablasts Through Epigenetic Regulation of BTB and CNC Homolog 2 by the Methyltransferase EZH2.
    Zhang M; Iwata S; Hajime M; Ohkubo N; Todoroki Y; Miyata H; Ueno M; Hao H; Zhang T; Fan J; Nakayamada S; Yamagata K; Tanaka Y
    Arthritis Rheumatol; 2020 Jul; 72(7):1143-1153. PubMed ID: 31961063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of B lymphocyte-induced maturation protein-1 reduces the production of autoantibody and alleviates symptoms of systemic lupus erythematosus.
    Luo J; Niu X; Zhang M; Zhang K; Chen M; Deng S
    Autoimmunity; 2015 Mar; 48(2):80-6. PubMed ID: 25347333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 is involved in the pathogenesis of system lupus erythematosus through promoting pathogenic antibody production.
    Zhang M; Yao C; Cai J; Liu S; Liu XN; Chen Y; Wang S; Ji P; Pan M; Kang Z; Wang Y
    J Transl Med; 2019 Jan; 17(1):37. PubMed ID: 30670047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of glutaminolysis ameliorates lupus by regulating T and B cell subsets and downregulating the mTOR/P70S6K/4EBP1 and NLRP3/caspase-1/IL-1β pathways in MRL/lpr mice.
    Zhang X; Wang G; Bi Y; Jiang Z; Wang X
    Int Immunopharmacol; 2022 Nov; 112():109133. PubMed ID: 36113317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ezh2-mediated epigenetic modification is required for allogeneic T cell-induced lupus disease.
    Zhen Y; Smith RD; Finkelman FD; Shao WH
    Arthritis Res Ther; 2020 Jun; 22(1):133. PubMed ID: 32503684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
    Mihaylova N; Bradyanova S; Chipinski P; Herbáth M; Chausheva S; Kyurkchiev D; Prechl J; Tchorbanov AI
    Autoimmunity; 2017 Jun; 50(4):257-268. PubMed ID: 28300427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4
    Peixoto TV; Carrasco S; Botte DAC; Catanozi S; Parra ER; Lima TM; Ugriumov N; Soriano FG; de Mello SBV; Rodrigues CM; Goldenstein-Schainberg C
    Adv Rheumatol; 2019 Jul; 59(1):30. PubMed ID: 31340848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactin-induced immunoglobulin and autoantibody production by peripheral blood mononuclear cells from systemic lupus erythematosus and normal individuals.
    Gutiérrez MA; Molina JF; Jara LJ; García C; Gutiérrez-Ureña S; Cuéllar ML; Gharavi A; Espinoza LR
    Int Arch Allergy Immunol; 1996 Mar; 109(3):229-35. PubMed ID: 8620091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgG4 Autoantibodies Attenuate Systemic Lupus Erythematosus Progression by Suppressing Complement Consumption and Inflammatory Cytokine Production.
    Pan Q; Xiao H; Shi L; He Y; Cai J; Wu J; Li A; Ye L; Yang C; Liu HF
    Front Immunol; 2020; 11():1047. PubMed ID: 32625200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant expansion of follicular helper T cell subsets in patients with systemic lupus erythematosus.
    Jin X; Chen J; Wu J; Lu Y; Li B; Fu W; Wang W; Cui D
    Front Immunol; 2022; 13():928359. PubMed ID: 36119056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell-activating factor (BAFF) from dendritic cells, monocytes and neutrophils is required for B cell maturation and autoantibody production in SLE-like autoimmune disease.
    Giordano D; Kuley R; Draves KE; Elkon KB; Giltiay NV; Clark EA
    Front Immunol; 2023; 14():1050528. PubMed ID: 36923413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice.
    Richards HB; Satoh M; Jennette JC; Okano T; Kanwar YS; Reeves WH
    Clin Exp Immunol; 1999 Mar; 115(3):547-53. PubMed ID: 10193432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of autoantibody production in pristane-induced murine lupus.
    Han S; Zhuang H; Xu Y; Lee P; Li Y; Wilson JC; Vidal O; Choi HS; Sun Y; Yang LJ; Reeves WH
    Arthritis Res Ther; 2015 Dec; 17():384. PubMed ID: 26717913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of XBP1s in B lymphocytes is critical for pristane-induced lupus nephritis in mice.
    Xiang L; Liu A; Xu G
    Am J Physiol Renal Physiol; 2020 May; 318(5):F1258-F1270. PubMed ID: 32249615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.